• Maarten Boers, Dorcas E Beaton, Beverley J Shea, Lara J Maxwell, Susan J Bartlett, Clifton O Bingham, Philip G Conaghan, Maria Antonietta D'Agostino, Maarten P de Wit, Laure Gossec, Lyn March, Lee S Simon, Jasvinder A Singh, Vibeke Strand, George A Wells, and Peter Tugwell.
• From the Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit; Department of Medical Humanities, VU University Medical Centre/EMGO+ institute, Amsterdam, the Netherlands; Institute for Work & Health and Institute for Health Policy Management and Evaluation, University of Toronto, Toronto; Centre for Practice-Changing Research, Ottawa Hospital Research Institute; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario; McGill Centre for Outcomes Research and Evaluation, Montreal, Quebec, Canada; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland; Medicine Service, VA Medical Center; Department of Medicine, School of Medicine, University of Alabama; Division of Epidemiology, School of Public Health, University of Alabama, Birmingham, Alabama; SDG LLC, Cambridge, Massachusetts; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, Boulogne-Billancourt; INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, Saint-Quentin en Yvelines; Sorbonne Université; Pitié Salpêtrière hospital, AP-HP, Rheumatology Department, Paris, France; Sydney Medical School, Institute of Bone and Joint Research; Department of Rheumatology, Royal North Shore Hospital, St Leonards, Australia.
• J Rheumatol. 2019 Aug 1; 46 (8): 1021-1027.

ObjectiveThe Outcome Measures in Rheumatology (OMERACT) Filter 2.0 framework was developed in 2014 to aid core outcome set development by describing the full universe of "measurable aspects of health conditions" from which core domains can be selected. This paper provides elaborations and updated concepts (OMERACT Filter 2.1).MethodsAt OMERACT 2018, we discussed challenges in the framework application caused by unclear or ambiguous wording and terms and incompletely developed concepts.ResultsThe updated OMERACT Filter 2.1 framework makes benefits and harms explicit, clarifies concepts, and improves naming of various terms.ConclusionWe expect that the Filter 2.1 framework will improve the process of core set development.

13 keywords...

hide…